Evidence syntheses in the registry — page 2
140 documents of type evidence synthesis.
Documents
-
In the population defined for obesity and overweight in adults, is the effect of Tirzepatide maintained across the full duration of the contributing trials?
High15 Apr 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Dulaglutide compared with the comparator used in its contributing trials on the anchor…
High14 Apr 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High14 Apr 2026 -
Does the cardiovascular effect of a glucagon-like peptide-1 receptor agonist established in secondary prevention extend to a primary-prevention population?
Moderate08 Apr 2026 -
Do incretin-based therapies increase the incidence of acute pancreatitis?
Moderate22 Mar 2026 -
In the population defined for obesity and overweight in adults, is the effect of CagriSema (cagrilintide with semaglutide) maintained across the full duration of the…
Moderate13 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its…
High11 Mar 2026 -
In the population defined for cutaneous wound healing and tissue repair, is the effect of Thymosin beta-4 maintained across the full duration of the contributing trials?
Low10 Mar 2026 -
In adults who have lost weight during treatment with an incretin receptor agonist, what happens to body weight after treatment is withdrawn?
Moderate09 Mar 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, is the effect of CJC-1295 maintained across the full duration of…
Low07 Mar 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate02 Mar 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Dulaglutide compared with the comparator…
High21 Feb 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate19 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor…
Moderate15 Feb 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Petrelintide compared with its…
Low11 Feb 2026 -
What is known about bacterial endotoxin content in peptides supplied for research and injected in practice?
Low05 Feb 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the…
Moderate04 Feb 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the effect of PT-141 (bremelanotide) compared with the comparator used in its…
Moderate04 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Lixisenatide maintained across the full duration of the contributing trials?
High03 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Exenatide compared with the comparator used…
High29 Jan 2026 -
To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?
Low26 Jan 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate23 Jan 2026 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the incidence of adverse events leading to discontinuation with…
Moderate23 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Petrelintide compared with the comparator used in its contributing trials on the…
Low19 Jan 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the…
High18 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with…
Moderate13 Jan 2026 -
In adults with metabolic dysfunction-associated steatohepatitis, do incretin receptor agonists improve histological outcomes, and does histological improvement predict…
Moderate12 Jan 2026 -
In adolescents with obesity, what is the effect of an incretin receptor agonist on body-mass index, and what is known about growth, bone accrual and pubertal outcomes?
Moderate09 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High07 Jan 2026 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with GHK-Cu compared with its…
Low02 Dec 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, is the effect of Teduglutide maintained across the full duration of the…
Moderate22 Nov 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate20 Nov 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the effect of Tesamorelin compared with the comparator used in its…
Moderate19 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Retatrutide maintained across the full duration of the contributing trials?
Moderate16 Nov 2025 -
In the population defined for obesity and overweight in adults, is the effect of Liraglutide maintained across the full duration of the contributing trials?
High15 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator…
Moderate13 Nov 2025
page 2 of 4